Stabilized coronavirus spike (S) protein immunogens and related vaccines
US10906944B2 · kind B2 · utility
24Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 14, 2020 |
| Grant date | Feb 2, 2021 |
| Priority date | — |
| Expiry date | Sep 14, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides redesigned soluble coronavirus S protein derived immunogens that are stabilized via specific modifications in the wildtype soluble S sequences. Also provided in the invention are nanoparticle vaccines that contain the redesigned soluble S immunogens displayed on self-assembling nanoparticles. Polynucleotide sequences encoding the redesigned immunogens and the nanoparticle vaccines are also provided in the invention. The invention further provides methods of using the vaccine compositions in various therapeutic applications, e.g., for preventing or treating coronaviral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.